Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: tezosentan Clear all
Completed Phase 3 Interventional

Tezosentan in Acute Heart Failure

NCT00525707
View directory record Official record
Conditions
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
Interventions
tezosentan
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
8
States / cities
Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 21, 2026, 4:29 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration

NCT00748371
View directory record Official record
Conditions
Platelet Aggregation
Interventions
aspirin, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 21, 2026, 4:29 PM EDT
Terminated No phase listed Observational

Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

NCT00722254
View directory record Official record
Conditions
Primary Myelofibrosis, Primary Pulmonary Hypertension, Secondary Myelofibrosis, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist

NCT05427162
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Prostacyclin Receptor Agonist
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 4 Interventional Results available

Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement

NCT01717209
View directory record Official record
Conditions
Heart Failure
Interventions
Nitric Oxide, Prostacyclin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 21, 2026, 4:29 PM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT03496207
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, Sotatercept, SOC
Drug · Other
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 3 Interventional

Tezosentan in the Treatment of Acute Heart Failure

NCT00524433
View directory record Official record
Conditions
Acute Heart Failure, Acute Decompensation of Chronic Heart Failure, New Onset of Heart Failure
Interventions
tezosentan, placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
16
States / cities
Huntsville, Alabama • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 21, 2026, 4:29 PM EDT
Completed No phase listed Observational

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

NCT01389206
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

NCT04452669
View directory record Official record
Conditions
COVID-19
Interventions
VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
Drug
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 21, 2026, 4:29 PM EDT
Active, not recruiting No phase listed Observational

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

NCT03045029
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Fresno, California • Los Angeles, California • San Juan Capistrano, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 2 Interventional

Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)

NCT01966302
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
BPS-314d-MR
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 21, 2026, 4:29 PM EDT
Recruiting Phase 4 Interventional

A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

NCT07759804
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
LIQ861 (treprostinil) inhalation powder
Combination Product
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 4:29 PM EDT
Terminated Phase 4 Interventional Results available

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

NCT00643604
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
treprostinil sodium
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 4 Interventional

Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

NCT04231084
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Vasodilator testing (Inhaled Nitric Oxide), Vasodilator testing (Inhaled Epoprostenol)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 4 Interventional Results available

CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet

NCT01329562
View directory record Official record
Conditions
Menstrual Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Springfield, Missouri • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 2 Interventional Results available

VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

NCT03122730
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
VentaProst
Combination Product
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 21, 2026, 4:29 PM EDT
Terminated Phase 2 Interventional

Tezosentan in Pulmonary Arterial Hypertension

NCT01077297
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tezosentan
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 2 Interventional

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

NCT06664801
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, Background PAH Therapy
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 21, 2026, 4:29 PM EDT
Terminated Phase 4 Interventional Results available

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

NCT00439946
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
treprostinil, Crono Five ambulatory pump
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 3 Interventional Results available

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

NCT03399604
View directory record Official record
Conditions
Primary Pulmonary Hypertension
Interventions
LIQ861 Inhaled Treprostinil
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
38
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 4 Interventional Results available

Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)

NCT01462565
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
current marketed FLOLAN (epoprostenol sodium), new thermo stable formulation of epoprostenol sodium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Miami Beach, Florida • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT03626688
View directory record Official record
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 21, 2026, 4:29 PM EDT
Completed Phase 2 Interventional

Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT00086463
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Ayerza Syndrome, Pulmonary Hypertension
Interventions
Iloprost or placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • La Jolla, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2011 · Synced Oct 21, 2026, 4:29 PM EDT